Introduction: IV haloperidol is used commonly for sedation in critically ill patients. However, IV haloperidol has been shown to cause the life-threatening ventricular tachyarrhythmia torsades de pointes. Mechanisms by which haloperidol causes torsades de pointes have not been widely investigated in controlled studies. 
caused by many drugs from numerous different therapeutic classes, including antibiotics, antiarrhythmic agents, antidepressant agents, antipsychotic agents, and a variety of others. 2 Episodes of torsades de pointes may be prolonged and sustained, and the arrhythmia may degenerate into fatal ventricular fibrillation. [3] [4] [5] IV haloperidol is widely used as a treatment for delusional agitation in critically ill patients. 6 Extremely high doses of IV haloperidol (as high as 975 mg per 24-h period) have been recommended by some clinicians for this indication. 6 Numerous cases of torsades de pointes associated with haloperidol appear in the literature. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The incidence of torsades de pointes associated with IV haloperidol use has been reported to be as high as 3.6% in critically ill patients. 15 Although the precise mechanism of torsades de pointes remains unknown, substantial evidence suggests that the arrhythmia is provoked by the initiation of early afterdepolarizations. 18 Early afterdepolarizations occur as a result of a failure of normal, complete membrane repolarization and can, therefore, be stimulated by conditions or drugs that prolong phase 2 or phase 3 membrane repolarization. 18 Early afterdepolarizations in turn result in a further delay in membrane repolarization, resulting in prolongation of the QTc interval on surface ECG. Drugs that produce early afterdepolarizations are those associated with the prolongation of monophasic action potential duration (APD) primarily through the prolongation of phase 3 membrane repolarization via blockade of delayed rectifier potassium channels. 18 Drugs that prolong APD, such as quinidine, 19 procainamide, 20 and erythromycin 21 have been shown to cause torsades de pointes.
Despite widespread use of high doses of IV haloperidol in critically ill patients and increasing numbers of reports of haloperidol-associated torsades de pointes, mechanisms by which the drug causes torsades de pointes have not been widely studied.
Haloperidol is known to cause prolongation of the QTc interval on surface ECG, suggesting that the drug may prolong ventricular effective refractory period (ERP) and APD, leading to early afterdepolarizations. In addition, the relationship between haloperidol dose and its electrophysiologic effects has not been extensively investigated. Therefore, the purpose of this study was to determine the effect of IV haloperidol on these parameters that are known to be associated with torsades de pointes. The following hypotheses were tested in this investigation: (1) IV haloperidol prolongs ventricular ERP; (2) IV haloperidol prolongs ventricular APD; and (3) the effects of IV haloperidol on ventricular ERP and APD are dose-related.
Materials and Methods
This was a randomized, placebo-controlled study conducted in 14 conditioned, heartworm-negative mongrel dogs of either sex (mean [Ϯ SD] weight, 23.2 Ϯ 2.7 kg; range, 18.2 to 27.2 kg). These experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. All procedures were approved by the Care of Experimental Animals Committee at Henry Ford Hospital.
Animal Preparation
Anesthesia was induced using a combination of diazepam, 0.17 mg/kg, oxymorphone, 0.22 mg/kg, and pentobarbital, 150 to 250 mg, dosed to effect. 22 Anesthesia was maintained using ␣-chloralose, 5 to 10 mg/kg/h, 21 adjusted using standard techniques. ␣-Chloralose was selected as the maintenance anesthetic because it exerts significantly less effect on the canine cardiovascular system than pentobarbital. 23 Animals were placed in the supine position on a surgical table covered with a warming blanket, and surface ECG leads were applied. The dogs were intubated and ventilated mechanically using a respirator (Harvard Apparatus; South Natick, MA) that was connected to a cuffed endotracheal tube. The left femoral artery and the right femoral vein were exposed surgically. A steerable, bipolar, 6F, silver-silver chloride combined contact monophasic action potential/pacing electrode catheter (EP Technologies Inc; Mountain View, CA) was advanced into the left ventricle via the femoral artery and was positioned at the apex. Another monophasic action potential catheter was advanced from the right femoral vein into the right ventricle and was positioned at the apex. Monophasic action potential signals were amplified and filtered using a universal signal amplifier (model No. 20-4615-58; Gould Instruments; Valley View, OH). In addition, a catheter-tip micromanometer (Millar Instruments; Houston, TX) was advanced into the aorta via the femoral artery for the measurement of systolic and diastolic BP. Catheters were positioned under fluoroscopic guidance. Surface ECG leads II and AVF, amplified monophasic action potentials, right ventricular electrogram, and arterial BP were displayed on an oscilloscope (Windograf model; Gould Instruments). Paper recordings were made on an electrostatic chart recorder (Gould Instruments).
Monophasic Action Potential Recordings
Monophasic action potentials were recorded from the right and left ventricles at paper speeds varying during each recording from 25 to 100 mm/s during ventricular pacing. Paper speeds of 25 mm/s were used to visualize action potentials to assure optimal shape and to assure that the catheter was in the correct position to make optimal ventricular contact in order that classic action potentials could be recorded. Action potential measurements were made using recordings performed at 100 mm/s. Monophasic action potentials were recorded at cycle lengths of 250, 300, and 450 ms (corresponding to paced heart rates of 240, 200, and 133 beats/min, respectively). Prior to the recording of monophasic action potentials, pacing was performed continuously for a minimum of 1 min to assure a "steady state." 21 Pacing was performed using a programmable stimulator (model DTU 210; Bloom Associates Ltd; Philadelphia, PA) generating rectangular impulses of 2 ms duration at a current equal to twice the diastolic pacing threshold. APD was measured from the beginning of phase 0 depolarization to the end of phase 4 repolarization. Left and right ventricular APDs were determined manually at 90% repolarization (APD 90 ) using standard methods. 21, 24 APD measurements were determined by the average of three consecutive ventricular paced complexes prior to and following drug administration.
Determination of Ventricular ERPs
ERPs were determined in the left and right ventricles. Pacing was performed at each cycle length in trains of eight beats (S 1 ). An initial premature test stimulus (S 2 ) of 2 ms duration was delivered in a coupling interval of 250 ms following the last paced beat. The interval between S 1 and S 2 was decreased in 5-ms decrements until the S 2 failed to produce ventricular depolarization twice. The ERP was defined as the longest S 1 -S 2 interval that failed to produce a propagated response.
Measurement of QTc Intervals
QT intervals were measured manually by a single investigator (JET) from ECGs obtained during each animal's natural (unpaced) heart rates. A minimum of five consecutive complexes was used for each QT interval measurement, and the mean value was used. The QT interval was measured from the beginning of the QRS complex to the visual return of the T wave to the isoelectric line. 25, 26 When the T wave was interrupted by a U wave, the end of the T wave was defined as the nadir between the T and the U wave. 25, 26 When the T wave appeared notched, the notch was disregarded (unless it was clearly a U wave interrupting the T wave), and the QT interval was measured as described above. QT intervals were corrected for heart rate using the method of Bazett. 27 
Drug Administration
Following surgical preparation and catheter insertion, animals were allowed to stabilize for 30 min to achieve stable BP (systolic BP, Ͼ 100 mm Hg; diastolic BP, Ͼ 70 mm Hg), heart rate, and oxygen saturation of Ͼ 90%. At baseline, the following measurements were recorded: left ventricular APD 90 ; right ventricular APD 90 ; left and right ventricular ERP; QTc interval; and arterial BP.
Haloperidol lactate was prepared in 5% dextrose in water (D5W) at a concentration of 2 mg/mL. Haloperidol doses were selected in order to approximate the range of doses that have been used in critically ill patients for the treatment of delirious agitation, and to approximate doses of IV haloperidol that have been reported to cause torsades de pointes in patients. 15 Haloperidol, 0.15 mg/kg, was administered IV over a period of 45 s (0.2 mg/kg/min). Ten minutes following the completion of the infusion, left and right ventricular APD 90 , left and right ventricular ERP, QTc interval, and BP measurements were repeated. Sixty minutes following the first infusion, haloperidol, 0.5 mg/kg, was administered IV at a rate of 0.2 mg/kg/min (over a period of 2.5 min; cumulative dose, 0.65 mg/kg). Ten minutes following the completion of the infusion, measurements were repeated. Sixty minutes following the completion of the previous haloperidol infusion, haloperidol, 2 mg/kg, was administered IV at the same infusion rate (over a period of 10 min; cumulative dose, 2.65 mg/kg). Measurements were repeated 10 min following the completion of the infusion. Sixty minutes following the completion of the previous haloperidol infusion, haloperidol, 3 mg/kg, was administered (over a period of 15 min; cumulative dose, 5.65 mg/kg). Measurements were repeated 10 min following the completion of the infusion. At each dose, left and right ventricular APD 90 were recorded during continuous pacing for 30 s at each of the three cycle lengths listed above. In the control (placebo) group, D5W was administered in volumes calculated to be the same as those given with haloperidol doses of 0.15, 0.5, 2, and 3 mg/kg. D5W was administered at infusion rates that were identical to the respective haloperidol infusion rates, and measurements were performed as described above. Intervals between successive doses of placebo were as described for the haloperidol group. On completion of the experiments, animals were killed using a commercial solution of pentobarbital and potassium chloride (Euthasol; Delmarva Laboratories; Midlothian, VA).
Statistical Analysis
APD 90 and ERP in each ventricle across the escalating doses were analyzed using univariate repeated-measures analysis of variance (ANOVA) with the Greenhouse-Geisser sphericity correction that is designed to prevent the potential violation of the variance-covariance assumption that underlies the repeatedmeasures ANOVA modeling. Significant differences by repeatedmeasures ANOVA were analyzed using the Tukey pairwise multiple comparison test. QTc interval measurements in the haloperidol group were not normally distributed and were therefore analyzed using the Friedman repeated-measures ANOVA on ranks. Significant differences were analyzed using the Tukey pairwise multiple comparison test. QTc interval measurements in the placebo group were analyzed using one-way repeatedmeasures ANOVA.
Results

Ventricular ERPs
The influence of IV haloperidol on left and right ventricular ERP measurements is presented in Figures 1 and 2 , respectively. Haloperidol administration resulted in a significant prolongation of ERP of 12 to 20% compared to pretreatment values. In contrast, left and right ventricular ERPs were not prolonged significantly compared to pretreatment values in the placebo group (Table 1) .
APD
The influence of IV haloperidol on left and right ventricular APD 90 is shown in Figures 3 and 4 , respectively. Left ventricular APD 90 at 300 ms was prolonged significantly in the haloperidol-treated animals. In general, mean left ventricular APD 90 was prolonged across the escalating doses of haloperidol by 7 to 11% compared to pretreatment values, although effects were not as consistent as, and exhibited greater variability than, the effects on ventricular ERP. In individual dogs, haloperidol administration resulted in prolongations of ventricular APD 90 by as much as 39%. The administration of placebo resulted in no significant changes in left or right ventricular APD 90 (Table 2) .
QTc Intervals
The influence of IV haloperidol on QTc intervals is presented in Figure 5 . Haloperidol produced significant prolongations in left and right ventricular QTc intervals compared to pretreatment values. QTc intervals were unchanged in the placebo group.
Effect of Haloperidol Dose on Changes in ERP and APD 90
Left and right ventricular ERP increased in a dose-related fashion at the 0. 15 at which points a plateau effect was reached with little additional increase at doses of 2.0 and 3.0 mg/kg. Left and right ventricular APD 90 increased in a dose-related fashion up to the 2.0 mg/kg dose, at which point APD 90 effects reached a plateau. Similarly, effects on the QTc interval were dose-related up to the 2.0 mg/kg dose, with little further change following administration of the 3.0 mg/kg dose. In summary, the electrophysiologic effects of haloperidol were related to dose, with a plateau reached at the 0.5 mg/kg dose for ERP measurements, and at the 2 mg/kg dose for the APD 90 and QTc interval measurements.
Discussion
In this investigation, haloperidol was found to produce in vivo electrophysiologic changes that are known to predispose patients to the development of torsades de pointes, prolonging ventricular ERP by 12 to 20%, and ventricular APD 90 by up to 11%. Haloperidol prolonged ventricular ERP in a doserelated fashion, producing maximum effects on ventricular ERP at doses of 0.5 mg/kg, with little additional prolongation achieved with an additional dose of 2.0 mg/kg or 3.0 mg/kg. Haloperidol also prolonged ventricular APD 90 and QTc intervals in a dose-related fashion, producing maximum effects at a dose of 2.0 mg/kg, with little further prolongation occurring at 3.0 mg/kg.
Numerous cases of haloperidol-associated QTc interval prolongation and/or torsades de pointes have been reported. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 28, 29 In addition to prolonging the QTc interval on surface ECG, IV haloperidol has been shown to increase 12-lead QT interval dispersion. 30 Haloperidol previously has been shown to inhibit voltage-activated potassium conduction in rat pheochromocytoma PC12 cells 31 and to inhibit conductance through cloned inactivated cardiac human ether-a-go-go-related gene potassium channels expressed in Xenopus oocytes. 32 However, few studies have investigated the in vivo cardiac electrophysiologic effects of IV haloperidol and their relationship to haloperidol dose. In an uncontrolled study, Satoh et al 33 administered one dose (3 mg/kg) of IV haloperidol to a small group (six dogs) of beagle dogs. Ventricular ERP, APD 90 , and QTc interval were prolonged. In another non-placebo-controlled study 34 in which the effects of haloperidol were compared with those of the antipsychotic agent aripiprazole in six dogs, ventricular ERP and APD 90 were prolonged following administration of IV haloperidol, 0.03 mg/kg, and were further increased following administration of haloperidol, 3.0 mg/kg. However, no doses between 0.03 and 3.0 mg/kg were administered, precluding a more complete analysis of the relationship between dose and cardiac electrophysiologic effects.
In the present investigation, we studied a larger group of animals than in these previous investigations, and we employed a placebo group in order to account for changes in cardiac electrophysiology that might occur as a result of anesthesia, intubation, surgical cutdowns, and other procedures employed in the experiments. These data confirmed that IV haloperidol significantly prolongs ventricular ERP and QTc interval, and, to a lesser degree, APD 90 . In addition, in the present study, we administered a wider range of haloperidol doses than in previous studies in order to more closely simulate the range of haloperidol doses that have been administered to critically ill patients for the management of delirious agitation, to simulate the range of doses that have been reported to cause torsades de pointes, 15 and to characterize the relationship between haloperidol dose and cardiac electrophysiologic effects within the range of clinically relevant doses. It is relatively common for critically ill patients to receive single IV haloperidol doses of 5 to 10 mg (0.075 to 0.15 mg/kg in a 70-kg patient) or higher. In some patients, torsades de pointes occurred after relatively low doses (ie, 10 mg over 4 h, or approximately 0.14 mg/kg in a 70-kg patient). 12 In other cases, however, torsades de pointes developed after cumulative haloperidol doses of 170 to 580 mg (approximately 2.5 to 8.3 mg/kg) over periods ranging from 24 to 96 h. 12, 15 These dose ranges are similar to the range of cumulative doses administered in this investigation. Therefore, the IV haloperidol doses administered in the present study are clinically relevant and similar to those previously associated with torsades de pointes. The data presented in this investigation provide important new information regarding the relationship between haloperidol dose and in vivo electrophysiologic changes known to promote torsades de pointes. In vivo effects of haloperidol on ventricular ERP occur at relatively low haloperidol doses, and the maximum effect occurred at 0.5 mg/kg, or approximately 35 mg in a 70-kg patient. These data support previous data from a study of haloperidol-induced torsades de pointes in critically ill patients, 15 in which the administration of IV haloperidol Ն 35 mg within a 24-h period was a significant risk factor for torsades de pointes, increasing the odds of the arrhythmia 14-fold. The prolonging effects of IV haloperidol on APD 90 and QTc interval also occurred at the lowest dose studied, and increased in a dose-related fashion, with a plateau at 2.0 mg/kg. The limitations of this investigation should be noted. While the results of this investigation show that haloperidol influences electrophysiologic variables known to predispose an animal to torsades de pointes, no animal actually developed torsades de pointes, and therefore direct evidence of haloperidol as a torsades de pointes-inducing agent was not provided in this study. However, the drug is wellrecognized as a torsades de pointes-provoking agent in humans, and these results indicate that haloperidol increases the risk of torsades de pointes. This investigation was designed to determine the effects of haloperidol on ERP and APD 90 at single endocar- dial sites in the left and right ventricle, but was not designed to assess the effects of the drug on intraventricular dispersion of refractoriness or repolarization, which may be important contributors to an increased risk of torsades de pointes. In addition, this study was not designed to determine whether the effects of haloperidol on ERP and APD 90 are dependent on rate (ie, "reverse-use dependent") as are the effects of many inhibitors of delayed rectifier potassium channels. The assessment of the potential in vivo rate dependency of haloperidol requires ablation of the atrioventricular node and pacing at longer cycle lengths (slower heart rates) than were tested in the present investigation. Further study is required to determine whether the electrophysiologic effects of haloperidol are dependent on heart rate.
In conclusion, in an anesthetized canine normal heart model, haloperidol influences electrophysiologic parameters known to predispose animals to torsades de pointes. The drug significantly prolongs ventricular ERP by 12 to 20%, and prolongs left ventricular APD 90 by 7 to 11%. The maximum effects of haloperidol occur at doses of 0.5 to 2.0 mg/kg, with little additional prolongation achieved with an additional dose of 3.0 mg/kg. Haloperidol significantly prolonged the QTc interval in this model. Therefore, to minimize the risk of torsades de pointes associated with IV haloperidol, the drug should be used with caution and at relatively low doses in patients with risk factors for torsades de pointes, and concomitant use of haloperidol with other drugs known to prolong ventricular repolarization should be avoided.
